- Home
- ENSC vs KZIA Comparison
ENSC vs KZIA Comparison
Compare ENSC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- KZIA
- Stock Information
- Founded
- ENSC 2003
- KZIA 1994
- Country
- ENSC United States
- KZIA Australia
- Employees
- ENSC N/A
- KZIA N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- KZIA Health Care
- Exchange
- ENSC Nasdaq
- KZIA Nasdaq
- Market Cap
- ENSC 5.5M
- KZIA 6.0M
- IPO Year
- ENSC N/A
- KZIA 1999
- Fundamental
- Price
- ENSC $2.31
- KZIA $0.69
- Analyst Decision
- ENSC
- KZIA Strong Buy
- Analyst Count
- ENSC 0
- KZIA 2
- Target Price
- ENSC N/A
- KZIA $11.50
- AVG Volume (30 Days)
- ENSC 31.4K
- KZIA 335.6K
- Earning Date
- ENSC 05-12-2025
- KZIA 04-11-2025
- Dividend Yield
- ENSC N/A
- KZIA N/A
- EPS Growth
- ENSC N/A
- KZIA N/A
- EPS
- ENSC N/A
- KZIA N/A
- Revenue
- ENSC $5,210,031.00
- KZIA $1,655,324.00
- Revenue This Year
- ENSC N/A
- KZIA N/A
- Revenue Next Year
- ENSC N/A
- KZIA N/A
- P/E Ratio
- ENSC N/A
- KZIA N/A
- Revenue Growth
- ENSC 133.58
- KZIA 248000.00
- 52 Week Low
- ENSC $2.12
- KZIA $0.76
- 52 Week High
- ENSC $14.67
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- ENSC 20.57
- KZIA 31.54
- Support Level
- ENSC $2.19
- KZIA $0.76
- Resistance Level
- ENSC $2.70
- KZIA $1.05
- Average True Range (ATR)
- ENSC 0.31
- KZIA 0.08
- MACD
- ENSC -0.05
- KZIA -0.01
- Stochastic Oscillator
- ENSC 5.26
- KZIA 8.44
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.